Feds Fund CAM Use Study

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 12
Volume 11
Issue 12

WASHINGTON-A 2-year, $1 million study by the Institute of Medicine (IOM) will explore the scientific and policy implications of complementary and alternative medicine (CAM). The study is being funded by 16 units of the National Institutes of Health, including the National Cancer Institute, and the Agency for Healthcare Research and Quality. The IOM, a part of the National Academy of Sciences, will name a committee of about 16 experts to carry out the study. Panel members will be chosen from among leading CAM specialists and more conventional disciplines.

WASHINGTON—A 2-year, $1 million study by the Institute of Medicine (IOM) will explore the scientific and policy implications of complementary and alternative medicine (CAM). The study is being funded by 16 units of the National Institutes of Health, including the National Cancer Institute, and the Agency for Healthcare Research and Quality. The IOM, a part of the National Academy of Sciences, will name a committee of about 16 experts to carry out the study. Panel members will be chosen from among leading CAM specialists and more conventional disciplines.

Articles in this issue
Tandem Transplants Increase CR, Reduce Treatment Mortality in Multiple Myeloma
Stereotactic Radiosurgery Benefits Brain Met Patients
Cancer Risk From Tainted Polio Vaccine Undetermined: IOM Report
Tailored Messages Motivate Women to Get Mammograms
Chemo/Rituximab Is Effective as First-Line CLL Therapy
Preoperative Capecitabine/RT Downstages Rectal Cancer
Intraoperative Lymphatic Mapping Enhances Cancer Staging
Rituximab Ups Survival in Aggressive and Indolent NHL
Genzyme Molecular Oncology Begins Kidney Cancer Vaccine Trial
Lower Breast Cancer Survival in Hispanics: New Mexico Study
Concurrent Chemo/RT More Likely to Save Larynx
Rituximab Improves Paclitaxel/ Topotecan Salvage Efficacy in NHL
CT Growth Assessment Reliably Diagnoses Solid Lung Nodules
Fludarabine Combos Showing Efficacy in Lymphomas
EntreMed’s Thalidomide Analog in Phase I Multiple Myeloma Trial
Recent Videos
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Related Content
The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line non-squamous NSCLC.

Subcutaneous Toripalimab Meets Primary End Points in Nonsquamous NSCLC

Roman Fabbricatore
November 30th 2025
Article

The developers plan to submit a new drug application to regulatory authorities for JS001sc for the treatment of first-line nonsquamous NSCLC.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?

Tim Cortese
November 29th 2025
Article

According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

HR 2541: How May Its Implementation Impact Radiation Oncology Practice?

Roman Fabbricatore
November 29th 2025
Article

Thomas Hope, MD, asserts that legislation aimed at resolving infiltration-related AEs does not address any relevant clinical issue.

As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

Ariana Pelosci
November 28th 2025
Article

A recent study found that the number of practicing oncologists is declining as the US population ages and cancer diagnoses continue to increase.